Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IMMH001, also known as SYL930, is an orally active compound that exhibits potent selectivity as an agonist for the S1P1 receptor, which is the sphingosine-1-phosphate receptor 1. This compound effectively reduces the levels of various chemokines and proinflammatory cytokines, such as IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 finds utility in research focused on rheumatoid arthritis (RA) [1] [2].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | IMMH001, also known as SYL930, is an orally active compound that exhibits potent selectivity as an agonist for the S1P1 receptor, which is the sphingosine-1-phosphate receptor 1. This compound effectively reduces the levels of various chemokines and proinflammatory cytokines, such as IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 finds utility in research focused on rheumatoid arthritis (RA) [1] [2]. |
In vivo | IMMH001 is metabolized into its active monophosphate ester form, (S)-IMMH001-P, by the action of sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) in vivo [1]. This compound effectively diminishes disease manifestations mediated by both Th1 (IL-1β, IL-18, and IP10) and Th2 (IL-5) cells in inflamed joints [2]. Administered orally at doses ranging from 0.3 to 2.4 mg/kg twice weekly for durations of 28 days in adjuvant-induced arthritis (AA) rats and 30 days in collagen-induced arthritis (CIA) rats, IMMH001 significantly alleviates joint damage in these models [2]. |
分子量 | 380.48 |
分子式 | C23H28N2O3 |
CAS No. | 1418093-75-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
IMMH001 1418093-75-0 Inhibitor inhibitor inhibit